NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

NCT04997148

CompletedN/A

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions: Relapsing-Remitting Multiple Sclerosis

Countries: United Kingdom

The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Physician diagnosis of HDA-RRMS as defined by clinical or radiological features
* Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and at least 3 years before enrolment
* Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per recommended dose in Year 1: 1.75 milligrams per kilogram \[mg/kg\] body weight, cumulatively)

Exclusion Criteria:

* Received cladribine tablet treatment within an interventional clinical trial during the study period
* Received treatment with any investigational therapy for RRMS in the 6 months prior to cladribine tablet treatment initiation

Locations (8)

Coventry, United Kingdom
Glasgow, United Kingdom
Glasgow, United Kingdom
Leicester, United Kingdom
London, United Kingdom
London, United Kingdom
Nottingham, United Kingdom
Salford, United Kingdom